Johnson Fistel, PLLP is investigating whether Replimune Group, Inc. or its executives violated securities laws after the FDA released briefing documents questioning the adequacy of evidence for Replimune's RP1 therapy combined with nivolumab. The FDA staff found the IGNYTE trial data insufficient to prove RP1's effectiveness, causing Replimune shares to fall about 30%. The investigation aims to determine if Replimune misled investors or delayed disclosure of critical information about RP1's regulatory prospects. Investors who suffered losses may be eligible to join the investigation.
Brunswick Corporation has released materials from its 2026 Investor Day, including a recorded strategy presentation, slides, and transcript, available on its website. The presentation details Brunswick's long-term growth strategy, strategic prioritie...
Dianthus Therapeutics announced inducement grants of stock options to six newly hired non-executive employees. The grants total 87,000 options with a 10-year term and an exercise price of $106.02 per share, vesting over four years. These grants were ...
Nasdaq has notified NusaTrip Incorporated that its securities will be delisted from the Nasdaq Stock Market on August 12, 2026, unless the company appeals. Trading in NusaTrip shares has been halted since October 23, 2025, following a suspension by t...
Nasdaq has notified Magnitude International Ltd. that its securities will be delisted from the Nasdaq Stock Market on August 12, 2026, unless the company appeals the decision. Trading in the company's shares has been halted since December 19, 2025, f...
Robinson Helicopter Company introduced its new R88 helicopter at LABACE 2026 in São Paulo, Brazil, marking its first appearance in South America. The R88 is a versatile, multi-mission helicopter designed to fill the gap between light single-engine an...
